GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Dr. Reddy's Laboratories Ltd (RDY) [hlAlert]

Rating:
Overweight
RDY
up 74.82 %

Dr. Reddy's Laboratories Ltd (RDY) rated Overweight by HSBC Securities

Posted on: Friday,  Jan 21, 2011  8:25 AM ET by HSBC Securities

HSBC Securities rated Overweight Dr. Reddy's Laboratories Ltd (NYSE: RDY) on 01/21/2011, when the stock price was $36.50.
Since then, Dr. Reddy's Laboratories Ltd has gained 74.82% as of 11/10/2015's recent price of $63.81.
If you would have followed this HSBC Securities's recommendation on RDY, you would have gained 74.82% of your investment in 1754 days.

Dr. Reddy?s Laboratories Limited (Dr. Reddy?s) is a global pharmaceutical company. The Company operates in three segments: Pharmaceutical Services and Active Ingredients (PSAI), which includes active pharmaceutical ingredients and intermediaries, which are the principal ingredients for finished pharmaceutical products; Global Generics, which consists of finished pharmaceutical products ready for consumption by the patient, and Proprietary Products, which involves the discovery of new chemical entities for subsequent commercialization and out-licensing. Dr. Reddy?s is vertically integrated and uses its pharmaceutical ingredients and intermediates in its own finished dosage products. The Company conducts basic research mainly in the areas of metabolic disorders, cardiovascular diseases and bacterial infection. On July 30, 2008, it acquired 85.69% interest in Perlecan Pharma Private Limited (Perlecan Pharma). Subsequently Perlecan Pharma became a wholly owned subsidiary of the Company.

HSBC has refined and refocused its Global Equities organisation, creating a lean and flexible business model built to meet the needs of global issuers and investors today and in the future. Acknowledging the changing demands of clients, we have also refined our research model, moving away from traditional maintenance to focus on long term, thematic research (a two-year-plus horizon) combined with short term (zero to three months), real-time, actionable ideas both for companies and sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/21/2011 8:25 AM Buy
None
36.50
as of 12/30/2011
1 Week down  -1.93 %
1 Month down  -2.03 %
3 Months down  -1.24 %
1 YTD down  -19.36 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy